Home/Biosimilar Atlas/Enoxaparin sodium/Inhixa

Inhixa

Enoxaparin sodium biosimilar developed by Techdow (Shenzhen Techdow Pharmaceutical). Reference product Clexane (Lovenox in the United States).

Brands by market: Inhixa (EU, UAE) · Commercial partner or holder: Techdow Pharma Netherlands · Company profile
FDANot listed
EMASep 2016authorised
MHRALicenseddate not shown
PMDANot listed
HCDec 2020approved
CDSCONot listed
EDEJun 2019registered
Approved or registered in 4 of 7 markets
Connections
Enoxaparin sodiummoleculeTechdowdeveloper4 of 7markets0trials behind it0other products, same developer6rival developers in its markets

About Inhixa

Inhixa is Techdow's enoxaparin, the first enoxaparin biosimilar approved in Europe, in September 2016. Techdow is a Chinese heparin manufacturer and sells Inhixa across Europe through its Dutch company. It is registered in the UAE in seven strengths, and in Canada the same product is approved as Redesca.

Status by market

FDA

United States

Not listed by FDA.

EMA

European Union · Inhixa

European Medicines Agency and European CommissionApproved
Brand
Inhixa
Holder or applicant
Techdow Pharma Netherlands B.V.
Pathway
Centralised (Article 10(4))
Approved
Sep 2016
Application or permission
EMEA/H/C/004264
Indications as licensed
VTE prophylaxis and treatment, unstable angina and NSTEMI, STEMI, haemodialysis circuit
Presentations
see SmPC
Remarks
First EU enoxaparin biosimilar.
Source
S017 (EMA) · checked Sep 2026
MHRA

United Kingdom · Inhixa

Medicines and Healthcare products Regulatory AgencyApproved
Brand
Inhixa
Holder or applicant
Not shown in the MHRA substance list
Pathway
UK marketing authorisation (Great Britain and, for EU-converted licences, Northern Ireland)
Approved
not published
Presentations
2,000 to 15,000 IU syringes; 30,000 and 50,000 IU multidose
Source
S023 (MHRA Products) · checked Sep 2026
PMDA

Japan

Not listed by PMDA.

HC

Canada · Redesca

Health CanadaApproved
Brand
Redesca
Holder or applicant
Shenzhen Techdow Pharmaceutical CO., LTD.
Pathway
Biosimilar biologic drug (Notice of Compliance)
Approved
Dec 2020
Application or permission
DIN 02509075, 02509083, 02509091, 02509105, 02509113, 02509121, 02509148, 02509156
Presentations
100, 30, 300, 40, 60, 80 mg; 120, 150 mg
Remarks
Also Redesca Hp.
Source
S022 (Health Canada) · checked Sep 2026
CDSCO

India

Not listed by CDSCO.

EDE

United Arab Emirates · Inhixa

Emirates Drug EstablishmentRegistered
Brand
Inhixa
Holder or applicant
SciencePharma Sp. z o.o., Poland (for Techdow) · UAE supplier Quadri Pharmaceuticals Store
Pathway
Registered medical product
Registered
Jun 2019
Presentations
2,000 IU/0.2 mL to 15,000 IU/mL PFS
Source
S018 (UAE Emirates Drug Establishment) · checked Sep 2026

Other developers in the same markets

Where Inhixa holds an approval, these are the other enoxaparin sodium biosimilars approved in that market.

MarketRivalsDevelopers (product)
MHRA2Not stated in the EDE directory (Ledraxen), Not stated in the MHRA list (Ghemaxan)
HC4Baxter (Axberi), Fresenius Kabi (Elonox), Juno Pharma Canada (Noromby), Sandoz (Inclunox)
EDE1Not stated in the EDE directory (Ledraxen)

Chronology

Sources

All enoxaparin sodium biosimilars

Planning enoxaparin sodium biosimilar development?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.